OBJECTIVE: To compare muscle strength (MS) and motor function in patients with Duchenne muscular dystrophy (DMD) receiving steroids for different times against the natural evolution of DMD described by Scott et al. METHOD: 90 patients with DMD (aged 5- 12 years), receiving steroids for one to seven years, were evaluated by Medical Research Council Scale (MRC) and Hammersmith motor ability score. The relation between MS and motor abilities measurement from our data and Scott's ones were ascertained statistically. RESULTS: The relation between patient's age and Hammersmith scores revealed decrease of 0.76 point per year for age against decrease of 2.23 points on Scott's study. The relation between MRC scale and patient's age showed decrease of 0.80 point per year of age against decrease of 3.65 points on Scott's study. CONCLUSION: In patients with DMD aged five to 12 years the progression of the disease is delayed by steroids and the motor function is less reduced than muscular strength.
OBJECTIVE: To compare muscle strength (MS) and motor function in patients with Duchenne muscular dystrophy (DMD) receiving steroids for different times against the natural evolution of DMD described by Scott et al. METHOD: 90 patients with DMD (aged 5- 12 years), receiving steroids for one to seven years, were evaluated by Medical Research Council Scale (MRC) and Hammersmith motor ability score. The relation between MS and motor abilities measurement from our data and Scott's ones were ascertained statistically. RESULTS: The relation between patient's age and Hammersmith scores revealed decrease of 0.76 point per year for age against decrease of 2.23 points on Scott's study. The relation between MRC scale and patient's age showed decrease of 0.80 point per year of age against decrease of 3.65 points on Scott's study. CONCLUSION: In patients with DMD aged five to 12 years the progression of the disease is delayed by steroids and the motor function is less reduced than muscular strength.
Authors: Saskia Koene; Ilse Dirks; Esmee van Mierlo; Pascal R de Vries; Anjo J W M Janssen; Jan A M Smeitink; Arjen Bergsma; Hans Essers; Kenneth Meijer; Imelda J M de Groot Journal: JIMD Rep Date: 2017-01-17
Authors: Lilian A Y Fernandes; Fátima A Caromano; Silvana M B Assis; Michele E Hukuda; Mariana C Voos; Eduardo V Carvalho Journal: Braz J Phys Ther Date: 2014 Nov-Dec Impact factor: 3.377
Authors: Saskia Koene; Jan C M Hendriks; Ilse Dirks; Lonneke de Boer; Maaike C de Vries; Mirian C H Janssen; Izelle Smuts; Cheuk-Wing Fung; Virginia C N Wong; I René F M de Coo; Katharina Vill; Claudia Stendel; Thomas Klopstock; Marni J Falk; Elizabeth M McCormick; Robert McFarland; Imelda J M de Groot; Jan A M Smeitink Journal: J Inherit Metab Dis Date: 2016-06-09 Impact factor: 4.982
Authors: Darlene L Machado; Elaine C Silva; Maria B D Resende; Celso R F Carvalho; Edmar Zanoteli; Umbertina C Reed Journal: BMC Res Notes Date: 2012-08-13
Authors: Priscila S Albuquerque; Mariana C Voos; Mariene S Simões; Joyce Martini; Carlos B M Monteiro; Fatima A Caromano Journal: Braz J Phys Ther Date: 2016-06-16 Impact factor: 3.377
Authors: Pedro Labisa; Valeska Andreozzi; Melina Mota; Susana Monteiro; Rita Alves; João Almeida; Björn Vandewalle; Jorge Felix; Katharina Buesch; Hugo Canhão; Igor Beitia Ortiz de Zarate Journal: Pharmacoecon Open Date: 2021-10-03
Authors: Nermina Ferizovic; Jessica Summers; Igor Beitia Ortiz de Zárate; Christian Werner; Joel Jiang; Erik Landfeldt; Katharina Buesch Journal: PLoS One Date: 2022-03-25 Impact factor: 3.240